Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
( 26 27 26 27 I-clinical_variable
ANC 27 30 27 30 I-clinical_variable
) 30 31 30 31 I-clinical_variable
greater 32 39 32 39 O
than 40 44 40 44 O
or 45 47 45 47 O
equal 48 53 48 53 O
to 54 56 54 56 O
1,500 57 62 57 62 B-lower_bound
/ 62 63 62 63 I-lower_bound
mcl 63 66 63 66 I-lower_bound
, 66 67 66 67 O
equivalent 68 78 68 78 O
to 79 81 79 81 O
Common 82 88 82 88 O
Terminology 89 100 89 100 O
Criteria 101 109 101 109 O
for 110 113 110 113 O
Adverse 114 121 114 121 O
Events 122 128 122 128 O
( 129 130 129 130 O
CTCAE 130 135 130 135 O
) 135 136 135 136 O
grade 137 142 137 142 O
1 143 144 143 144 O

Alkaline 0 8 145 153 B-clinical_variable
phosphatase 9 20 154 165 I-clinical_variable
less 21 25 166 170 O
than 26 30 171 175 O
or 31 33 176 178 O
equal 34 39 179 184 O
to 40 42 185 187 O
2.5 43 46 188 191 B-upper_bound
x 47 48 192 193 I-upper_bound
ULN 49 52 194 197 I-upper_bound
( 53 54 198 199 O
CTCAE 54 59 199 204 O
grade 60 65 205 210 O
1 66 67 211 212 O
) 67 68 212 213 O

Any 0 3 214 217 O
hormonal 4 12 218 226 B-treatment
therapy 13 20 227 234 I-treatment
directed 21 29 235 243 O
at 30 32 244 246 O
the 33 36 247 250 O
malignant 37 46 251 260 B-cancer
tumor 47 52 261 266 I-cancer
must 53 57 267 271 O
be 58 60 272 274 O
discontinued 61 73 275 287 O
at 74 76 288 290 O
least 77 82 291 296 O
one 83 86 297 300 B-upper_bound
week 87 91 301 305 O
prior 92 97 306 311 O
to 98 100 312 314 O
registration 101 113 315 327 O
; 113 114 327 328 O
continuation 115 127 329 341 O
of 128 130 342 344 O
hormone 131 138 345 352 B-treatment
replacement 139 150 353 364 I-treatment
therapy 151 158 365 372 I-treatment
is 159 161 373 375 O
permitted 162 171 376 385 O

Bilirubin 0 9 386 395 B-clinical_variable
less 10 14 396 400 O
than 15 19 401 405 O
or 20 22 406 408 O
equal 23 28 409 414 O
to 29 31 415 417 O
1.5 32 35 418 421 B-upper_bound
x 36 37 422 423 I-upper_bound
upper 38 43 424 429 I-upper_bound
limit 44 49 430 435 I-upper_bound
of 50 52 436 438 I-upper_bound
normal 53 59 439 445 I-upper_bound
( 60 61 446 447 I-upper_bound
ULN 61 64 447 450 I-upper_bound
) 64 65 450 451 I-upper_bound
( 66 67 452 453 O
CTCAE 67 72 453 458 O
grade 73 78 459 464 O
1 79 80 465 466 O
) 80 81 466 467 O

Creatinine 0 10 468 478 B-clinical_variable
no 11 13 479 481 O
greater 14 21 482 489 O
than 22 26 490 494 O
the 27 30 495 498 O
institutional 31 44 499 512 O
upper 45 50 513 518 O
limits 51 57 519 525 O
of 58 60 526 528 O
normal 61 67 529 535 O

Neuropathy 0 10 536 546 B-chronic_disease
( 11 12 547 548 I-chronic_disease
sensory 12 19 548 555 I-chronic_disease
and 20 23 556 559 I-chronic_disease
motor 24 29 560 565 I-chronic_disease
) 29 30 565 566 I-chronic_disease
less 31 35 567 571 O
than 36 40 572 576 O
or 41 43 577 579 O
equal 44 49 580 585 O
to 50 52 586 588 O
CTCAE 53 58 589 594 B-clinical_variable
grade 59 64 595 600 B-lower_bound
1 65 66 601 602 I-lower_bound

No 0 2 603 605 O
signs 3 8 606 611 O
of 9 11 612 614 O
clinically 12 22 615 625 O
significant 23 34 626 637 O
hearing 35 42 638 645 B-chronic_disease
loss 43 47 646 650 I-chronic_disease

Patients 0 8 651 659 O
must 9 13 660 664 O
be 14 16 665 667 O
entered 17 24 668 675 O
within 25 31 676 682 O
8 32 33 683 684 B-upper_bound
weeks 34 39 685 690 I-upper_bound
after 40 45 691 696 O
surgery 46 53 697 704 B-treatment
performed 54 63 705 714 O
for 64 67 715 718 O
either 68 74 719 725 O
1 75 76 726 727 O
) 76 77 727 728 O
initial 78 85 729 736 B-treatment
diagnosis 86 95 737 746 I-treatment
, 95 96 746 747 O
staging 97 104 748 755 B-treatment
, 104 105 755 756 O
and/or 106 112 757 763 O
cytoreduction 113 126 764 777 B-treatment
, 126 127 777 778 O
or 128 130 779 781 O
2 131 132 782 783 O
) 132 133 783 784 O
( 134 135 785 786 O
if 135 137 786 788 O
done 138 142 789 793 O
) 142 143 793 794 O
management 144 154 795 805 O
of 155 157 806 808 O
recurrent 158 167 809 818 O
disease 168 175 819 826 O
in 176 178 827 829 O
a 179 180 830 831 O
chemonaive 181 191 832 842 O
patient 192 199 843 850 O

Patients 0 8 851 859 O
must 9 13 860 864 O
have 14 18 865 869 O
a 19 20 870 871 O
Gynecologic 21 32 872 883 B-clinical_variable
Oncology 33 41 884 892 I-clinical_variable
Group 42 47 893 898 I-clinical_variable
( 48 49 899 900 I-clinical_variable
GOG 49 52 900 903 I-clinical_variable
) 52 53 903 904 I-clinical_variable
performance 54 65 905 916 I-clinical_variable
grade 66 71 917 922 O
of 72 74 923 925 O
0 75 76 926 927 B-lower_bound
, 76 77 927 928 O
1 78 79 929 930 O
, 79 80 930 931 O
or 81 83 932 934 O
2 84 85 935 936 B-upper_bound

Patients 0 8 937 945 O
must 9 13 946 950 O
have 14 18 951 955 O
newly 19 24 956 961 O
diagnosed 25 34 962 971 O
, 34 35 971 972 O
stage 36 41 973 978 B-lower_bound
IIA 42 45 979 982 I-lower_bound
? 46 47 983 984 O
IV 48 50 985 987 B-upper_bound
disease 51 58 988 995 O
and 59 62 996 999 O
must 63 67 1000 1004 O
be 68 70 1005 1007 O
entered 71 78 1008 1015 O
within 79 85 1016 1022 O
eight 86 91 1023 1028 B-upper_bound
weeks 92 97 1029 1034 I-upper_bound
from 98 102 1035 1039 O
surgery 103 110 1040 1047 B-treatment
; 110 111 1047 1048 O
they 112 116 1049 1053 O
may 117 120 1054 1057 O
have 121 125 1058 1062 O
either 126 132 1063 1069 O
measurable 133 143 1070 1080 O
residual 144 152 1081 1089 O
disease 153 160 1090 1097 O
by 161 163 1098 1100 O
Response 164 172 1101 1109 O
Evaluation 173 183 1110 1120 O
Criteria 184 192 1121 1129 O
In 193 195 1130 1132 O
Solid 196 201 1133 1138 O
Tumors 202 208 1139 1145 O
( 209 210 1146 1147 O
RECIST 210 216 1147 1153 O
) 216 217 1153 1154 O
criteria 218 226 1155 1163 O
, 226 227 1163 1164 O
or 228 230 1165 1167 O
they 231 235 1168 1172 O
may 236 239 1173 1176 O
have 240 244 1177 1181 O
no 245 247 1182 1184 O
measurable 248 258 1185 1195 O
residual 259 267 1196 1204 O
disease 268 275 1205 1212 O
; 275 276 1212 1213 O
OR 277 279 1214 1216 O
, 279 280 1216 1217 O
they 281 285 1218 1222 O
must 286 290 1223 1227 O
have 291 295 1228 1232 O
biopsy 296 302 1233 1239 O
- 302 303 1239 1240 O
proven 303 309 1240 1246 O
recurrent 310 319 1247 1256 O
disease 320 327 1257 1264 O
of 328 330 1265 1267 O
any 331 334 1268 1271 O
stage 335 340 1272 1277 O
and 341 344 1278 1281 O
have 345 349 1282 1286 O
never 350 355 1287 1292 O
received 356 364 1293 1301 O
cytotoxic 365 374 1302 1311 B-treatment
chemotherapy 375 387 1312 1324 I-treatment

Patients 0 8 1325 1333 O
must 9 13 1334 1338 O
have 14 18 1339 1343 O
pulmonary 19 28 1344 1353 O
function 29 37 1354 1362 O
sufficient 38 48 1363 1373 O
to 49 51 1374 1376 O
receive 52 59 1377 1384 O
bleomycin 60 69 1385 1394 B-treatment
, 69 70 1394 1395 O
with 71 75 1396 1400 O
normal 76 82 1401 1407 O
lung 83 87 1408 1412 O
expansion 88 97 1413 1422 O
, 97 98 1422 1423 O
absence 99 106 1424 1431 O
of 107 109 1432 1434 O
crackles 110 118 1435 1443 O
on 119 121 1444 1446 O
auscultation 122 134 1447 1459 O
, 134 135 1459 1460 O
and 136 139 1461 1464 O
normal 140 146 1465 1471 O
carbon 147 153 1472 1478 B-clinical_variable
monoxide 154 162 1479 1487 I-clinical_variable
diffusion 163 172 1488 1497 I-clinical_variable
( 173 174 1498 1499 I-clinical_variable
DLCO 174 178 1499 1503 I-clinical_variable
) 178 179 1503 1504 I-clinical_variable
, 179 180 1504 1505 O
defined 181 188 1506 1513 O
as 189 191 1514 1516 O
greater 192 199 1517 1524 O
than 200 204 1525 1529 O
80 205 207 1530 1532 B-lower_bound
% 207 208 1532 1533 I-lower_bound
predicted 209 218 1534 1543 O

Patients 0 8 1544 1552 O
who 9 12 1553 1556 O
have 13 17 1557 1561 O
received 18 26 1562 1570 O
any 27 30 1571 1574 O
prior 31 36 1575 1580 B-treatment
cytotoxic 37 46 1581 1590 I-treatment
chemotherapy 47 59 1591 1603 I-treatment
or 60 62 1604 1606 O
biologics 63 72 1607 1616 B-treatment
for 73 76 1617 1620 O
sex 77 80 1621 1624 B-cancer
cord 81 85 1625 1629 I-cancer
- 85 86 1629 1630 I-cancer
stromal 86 93 1630 1637 I-cancer
tumors 94 100 1638 1644 I-cancer
( 101 102 1645 1646 I-cancer
SCSTs 102 107 1646 1651 I-cancer
) 107 108 1651 1652 I-cancer

Patients 0 8 1653 1661 O
with 9 13 1662 1666 O
a 14 15 1667 1668 O
history 16 23 1669 1676 O
of 24 26 1677 1679 O
hypersensitivity 27 43 1680 1696 O
reactions 44 53 1697 1706 O
to 54 56 1707 1709 O
prior 57 62 1710 1715 B-allergy_name
chemotherapy 63 75 1716 1728 I-allergy_name
administered 76 88 1729 1741 O
for 89 92 1742 1745 O
previous 93 101 1746 1754 O
cancer 102 108 1755 1761 B-cancer
diagnoses 109 118 1762 1771 O
are 119 122 1772 1775 O
eligible 123 131 1776 1784 O
to 132 134 1785 1787 O
participate 135 146 1788 1799 O
in 147 149 1800 1802 O
the 150 153 1803 1806 O
study 154 159 1807 1812 O
, 159 160 1812 1813 O
unless 161 167 1814 1820 O
the 168 171 1821 1824 O
hypersensitivity 172 188 1825 1841 O
reaction 189 197 1842 1850 O
consisted 198 207 1851 1860 O
of 208 210 1861 1863 O
anaphylaxis 211 222 1864 1875 B-chronic_disease
not 223 226 1876 1879 O
amenable 227 235 1880 1888 O
to 236 238 1889 1891 O
desensitization 239 254 1892 1907 B-treatment

Patients 0 8 1908 1916 O
with 9 13 1917 1921 O
a 14 15 1922 1923 O
history 16 23 1924 1931 O
of 24 26 1932 1934 O
other 27 32 1935 1940 O
invasive 33 41 1941 1949 B-cancer
malignancies 42 54 1950 1962 I-cancer
, 54 55 1962 1963 O
with 56 60 1964 1968 O
the 61 64 1969 1972 O
exception 65 74 1973 1982 O
of 75 77 1983 1985 O
non 78 81 1986 1989 B-cancer
- 81 82 1989 1990 I-cancer
melanoma 82 90 1990 1998 I-cancer
skin 91 95 1999 2003 I-cancer
cancer 96 102 2004 2010 I-cancer
, 102 103 2010 2011 O
are 104 107 2012 2015 O
excluded 108 116 2016 2024 O
if 117 119 2025 2027 O
there 120 125 2028 2033 O
is 126 128 2034 2036 O
any 129 132 2037 2040 O
evidence 133 141 2041 2049 O
of 142 144 2050 2052 O
other 145 150 2053 2058 O
malignancy 151 161 2059 2069 B-cancer
being 162 167 2070 2075 O
present 168 175 2076 2083 O
within 176 182 2084 2090 O
the 183 186 2091 2094 O
last 187 191 2095 2099 B-upper_bound
five 192 196 2100 2104 I-upper_bound
years 197 202 2105 2110 I-upper_bound

Patients 0 8 2111 2119 O
with 9 13 2120 2124 O
histologically 14 28 2125 2139 O
confirmed 29 38 2140 2149 O
ovarian 39 46 2150 2157 B-cancer
stromal 47 54 2158 2165 I-cancer
tumor 55 60 2166 2171 I-cancer
[ 61 62 2172 2173 O
granulosa 62 71 2173 2182 B-cancer
cell 72 76 2183 2187 I-cancer
tumor 77 82 2188 2193 I-cancer
, 82 83 2193 2194 O
ganulosa 84 92 2195 2203 B-cancer
cell 93 97 2204 2208 I-cancer
- 97 98 2208 2209 I-cancer
theca 98 103 2209 2214 I-cancer
cell 104 108 2215 2219 I-cancer
tumor 109 114 2220 2225 I-cancer
, 114 115 2225 2226 O
Sertoli 116 123 2227 2234 B-cancer
- 123 124 2234 2235 I-cancer
Leydig 124 130 2235 2241 I-cancer
cell 131 135 2242 2246 I-cancer
tumor 136 141 2247 2252 I-cancer
( 142 143 2253 2254 O
androblastoma 143 156 2254 2267 B-cancer
) 156 157 2267 2268 O
, 157 158 2268 2269 O
steroid 159 166 2270 2277 B-cancer
( 167 168 2278 2279 I-cancer
lipid 168 173 2279 2284 I-cancer
) 173 174 2284 2285 I-cancer
cell 175 179 2286 2290 I-cancer
tumor 180 185 2291 2296 I-cancer
, 185 186 2296 2297 O
gynandroblastoma 187 203 2298 2314 B-cancer
, 203 204 2314 2315 O
unclassified 205 217 2316 2328 O
sex 218 221 2329 2332 B-cancer
cord 222 226 2333 2337 I-cancer
- 226 227 2337 2338 I-cancer
stromal 227 234 2338 2345 I-cancer
tumor 235 240 2346 2351 I-cancer
, 240 241 2351 2352 O
sex 242 245 2353 2356 B-cancer
cord 246 250 2357 2361 I-cancer
tumor 251 256 2362 2367 I-cancer
with 257 261 2368 2372 O
annular 262 269 2373 2380 O
tubules 270 277 2381 2388 O
] 277 278 2388 2389 O

Platelet 0 8 2390 2398 B-clinical_variable
greater 9 16 2399 2406 O
than 17 21 2407 2411 O
or 22 24 2412 2414 O
equal 25 30 2415 2420 O
to 31 33 2421 2423 O
100,000 34 41 2424 2431 B-lower_bound
/ 41 42 2431 2432 I-lower_bound
mcl 42 45 2432 2435 I-lower_bound

Recovery 0 8 2436 2444 O
from 9 13 2445 2449 O
effects 14 21 2450 2457 O
of 22 24 2458 2460 O
recent 25 31 2461 2467 B-treatment
surgery 32 39 2468 2475 I-treatment
, 39 40 2475 2476 O
radiotherapy 41 53 2477 2489 B-treatment
, 53 54 2489 2490 O
or 55 57 2491 2493 O
chemotherapy 58 70 2494 2506 B-treatment

Serum 0 5 2507 2512 B-clinical_variable
glutamic 6 14 2513 2521 I-clinical_variable
oxaloacetic 15 26 2522 2533 I-clinical_variable
transaminase 27 39 2534 2546 I-clinical_variable
( 40 41 2547 2548 I-clinical_variable
SGOT 41 45 2548 2552 I-clinical_variable
) 45 46 2552 2553 I-clinical_variable
( 47 48 2554 2555 I-clinical_variable
aspartate 48 57 2555 2564 I-clinical_variable
aminotransferase 58 74 2565 2581 I-clinical_variable
[ 75 76 2582 2583 I-clinical_variable
AST 76 79 2583 2586 I-clinical_variable
] 79 80 2586 2587 I-clinical_variable
) 80 81 2587 2588 I-clinical_variable
less 82 86 2589 2593 O
than 87 91 2594 2598 O
or 92 94 2599 2601 O
equal 95 100 2602 2607 O
to 101 103 2608 2610 O
3.0 104 107 2611 2614 B-upper_bound
x 108 109 2615 2616 I-upper_bound
ULN 110 113 2617 2620 I-upper_bound
( 114 115 2621 2622 O
CTCAE 115 120 2622 2627 B-clinical_variable
grade 121 126 2628 2633 O
1 127 128 2634 2635 O
) 128 129 2635 2636 O

Woman 0 5 2637 2642 B-gender
who 6 9 2643 2646 O
are 10 13 2647 2650 O
pregnant 14 22 2651 2659 B-pregnancy
or 23 25 2660 2662 O
breastfeeding 26 39 2663 2676 O

